Back to Newsroom
Back to Newsroom

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of DOYU, ANAB and BBBY

Friday, 15 May 2020 03:25 PM

The Klein Law Firm

Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / May 15, 2020 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

DouYu International Holdings Limited (NASDAQ:DOYU)
Affected investors purchased DOYU stock in the initial public offering pursuant and/or traceable to the documents used by defendants to conduct that offering.
Lead Plaintiff Deadline: May 26, 2020

During the class period, DouYu International Holdings Limited allegedly made materially false and/or misleading statements and/or failed to disclose that: as of the initial public offering: (i) DouYu's risks related to its top streamers had materialized, including that: (a) a top streamer was actively misrepresenting herself on DouYu's platform;and (b) costs associated with retaining top streamers was swelling; (ii) DouYu did not ensure that all of its products were fully compliant with current regulatory requirements before those products became available online; and (iii) key interactive features of DouYu's "lucky draw"were non-compliant with current regulatory requirements.

Learn about your recoverable losses in DOYU: http://www.kleinstocklaw.com/pslra-1/douyu-international-holdings-limited-loss-submission-form?id=6629&from=1

AnaptysBio, Inc. (NASDAQ:ANAB)
Class Period: October 10, 2017 - November 7, 2019
Lead Plaintiff Deadline: May 26, 2020

Throughout the class period, AnaptysBio, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) AnaptysBio failed to disseminate important data from the Company's Phase 2a trial in atopic dermatitis, including the timing and extent of patients' use of topical corticosteroids as a rescue therapy during the study and whether any of the patients that utilized rescue therapy were classified as responders at a given time;and (ii) the Company's statements omitted key information from the Company's Phase 2a trial in peanut allergy, including patients' average cumulative peanut dose tolerated at day 14 after the administration of etokimab or placebo as well as whether the Company's decision to exclude 20% of the patients enrolled in the study from the interim analysis due to their mild symptoms was retrospective; and (ii) as a result of the foregoing, Defendants' positive statements about the efficacy and prospects of AnaptysBio's lead drug asset in the treatment of atopic dermatitis and peanut allergy were materially false and/or misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in ANAB: http://www.kleinstocklaw.com/pslra-1/anaptysbio-inc-loss-submission-form?id=6629&from=1

Bed Bath & Beyond Inc. (NASDAQ:BBBY)
Class Period: October 2, 2019 - February 11, 2020
Lead Plaintiff Deadline: June 15, 2020

The complaint alleges Bed Bath & Beyond Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) due to "aggressive disposition of inventory," the Company lacked sufficient inventory in key categories to support holiday sales; (2) the Company's internal control over inventory levels and financial reporting was not effective; (3) as a result of the foregoing, the Company was likely to experience reduced sales; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in BBBY: http://www.kleinstocklaw.com/pslra-1/bed-bath-beyond-inc-loss-submission-form?id=6629&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Law Offices of Vincent Wong

Topic:
Lawsuits
Back to newsroom
Back to Newsroom
Share by: